NICE's approval of adalimumab for the treatment of hidradenitis suppurativa is contingent on the manufacturer providing the TNF-inhibiting antibody at the price agreed in the patient access scheme.
Healthcare professionals should assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as:
- a reduction of 25% or more in the total abscess and inflammatory nodule count, and
- no increase in abscesses and draining fistulas.
Approved in 2015 for the treatment of hidradenitis suppurativa, Humira is the first licensed option for the chronic systemic inflammatory disorder, which is characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.